This inventor holds 1 USPTO granted patent. Top assignees: Kringle Pharma Inc., Osaka University. Active years: 2013.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 14 
1 out of 1,045 
Years Active: 2013
Title: Daisuke Miyazawa: Innovator in Polyglutamine Aggregation Treatment
Introduction
Daisuke Miyazawa is a notable inventor based in Nagoya, Japan. He has made significant contributions to the field of medical science, particularly in the treatment of diseases caused by polyglutamine aggregation. His innovative approach has the potential to impact many lives.
Latest Patents
Miyazawa holds a patent for an agent designed to treat polyglutamine aggregation-caused diseases or suppress their onset. The patent, titled "Agent for treating polyglutamine aggregation-caused disease or suppressing onset thereof," includes as active ingredients HGF protein, a partial peptide of HGF protein that is substantially equivalent in activity to HGF protein, or a salt of either of them. He has 1 patent to his name.
Career Highlights
Throughout his career, Daisuke Miyazawa has worked with esteemed institutions such as Osaka University and Kringle Pharma Inc. His work has been instrumental in advancing research in his field.
Collaborations
Miyazawa has collaborated with notable colleagues, including Toshikazu Nakamura and Hiroshi Funakoshi. Their combined expertise has contributed to the success of their research endeavors.
Conclusion
Daisuke Miyazawa's innovative work in treating polyglutamine aggregation-caused diseases showcases his dedication to advancing medical science. His contributions are paving the way for future breakthroughs in this critical area of research.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile